INCY - Incyte Non-GAAP EPS of $0.60 misses by $0.10 revenue of $823.03M misses by $20.62M
- Incyte press release ( NASDAQ: INCY ): Q3 Non-GAAP EPS of $0.60 misses by $0.10 .
- Revenue of $823.03M (+1.2% Y/Y) misses by $20.62M .
-
Total net product revenues grew to $713 million (+20% Y/Y) as a result of strong Jakafi ® (ruxolitinib) and Opzelura ™ (ruxolitinib) cream net product revenues
-
Jakafi net product revenues of $620 million in Q3’22 (+13% Y/Y); raising the bottom end of full year guidance to a new range of $2.38 to $2.40 billion
-
Opzelura net product revenues of $38 million in Q3'22 driven by robust demand and broadening payer access; launch in vitiligo underway
-
Pipeline progresses with positive povorcitinib data in hidradenitis suppurativa at EADV, oral PD-L1 update at SITC and the pending acquisition of Villaris Therapeutics and auremolimab, a novel anti-IL-15R? mAb
For further details see:
Incyte Non-GAAP EPS of $0.60 misses by $0.10, revenue of $823.03M misses by $20.62M